FDS:NYSEFactSet Research Systems Inc. Analysis
Data as of 2026-05-26 - not real-time
$232.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
FactSet (FDS) is trading at $232, comfortably above its 20‑day ($221) and 50‑day ($219) SMAs but still below the 200‑day SMA ($269), indicating short‑term strength within a longer‑term downtrend. Technicals are supportive – RSI sits at 57.7, the MACD histogram is positive and the signal is bullish, while volume is on the rise. The stock trades at a forward PE of 11.9, well below the industry average of 16.8, and a DCF‑derived fair value of $250 suggests roughly 9% upside. Fundamentals are solid: revenue grew 7% YoY, operating margin is near 30%, ROE stands at 28%, and free cash flow comfortably covers the modest dividend payout (2% yield, 28% payout ratio). The balance sheet shows elevated leverage (Debt/Equity ~73) but strong cash generation mitigates immediate solvency concerns.
Recent material news highlights an upcoming ex‑dividend date, reinforcing the dividend’s attractiveness, and a planned Whole Portfolio Distribution launch that could broaden recurring revenue streams. While the stock has underperformed peers in the past few sessions, the combination of undervaluation, robust profitability, and dividend sustainability under a low‑beta profile positions FactSet as a compelling medium‑ to long‑term buy.
Recent material news highlights an upcoming ex‑dividend date, reinforcing the dividend’s attractiveness, and a planned Whole Portfolio Distribution launch that could broaden recurring revenue streams. While the stock has underperformed peers in the past few sessions, the combination of undervaluation, robust profitability, and dividend sustainability under a low‑beta profile positions FactSet as a compelling medium‑ to long‑term buy.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and rising volume
- Price near short‑term support/resistance zone
- Dividend yield provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervaluation relative to DCF and peers
- Strong earnings growth and high ROE
- Upcoming product launch expanding recurring revenue
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Durable subscription‑based business model
- Attractive dividend yield with sustainable payout
- Consistent profitability and low market beta
Key Metrics & Analysis
Financial Health
Revenue Growth7.10%
Profit Margin24.48%
P/E Ratio14.9
ROE28.08%
ROA10.91%
Debt/Equity72.97
P/B Ratio4.0
Op. Cash Flow$798.9M
Free Cash Flow$590.2M
Industry P/E16.8
Technical Analysis
TrendNeutral
RSI57.7
Support$198.00
Resistance$236.17
MA 20$221.10
MA 50$219.23
MA 200$269.41
MACDBullish
VolumeIncreasing
Fear & Greed Index91.64
Valuation
Fair Value$250.46
Target Price$252.44
Upside/Downside8.81%
GradeUndervalued
TypeBlend
Dividend Yield2.00%
Risk Assessment
Beta0.29
Volatility50.59%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.